Burning Rock Biotech (BNR) Net Cash Flow (2019 - 2026)

Burning Rock Biotech's Net Cash Flow history runs 8 years deep, the most recent figure standing at -$4.3 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 24.76% year-over-year to -$4.3 million; the TTM figure through Mar 2026 stood at -$15.8 million (up 58.81% YoY), while the FY2025 annual figure was -$4.4 million, up 67.09% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$4.3 million, down from -$4.1 million in the prior quarter.
• The five-year high for Net Cash Flow was $1.9 million in Q3 2025, with the low at -$25.4 million in Q1 2022.
• The 5-year median for Net Cash Flow is -$11.5 million (2023), against an average of -$11.6 million.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow slumped 403.89% in 2024, then soared 111.71% in 2025.
• Burning Rock Biotech's Net Cash Flow stood at -$22.8 million in 2022, then surged by 88.7% to -$2.6 million in 2023, then plunged by 403.89% to -$13.0 million in 2024, then jumped by 68.64% to -$4.1 million in 2025, then slipped by 5.86% to -$4.3 million in 2026.
• Business Quant data shows BNR's Net Cash Flow at -$4.3 million in Q1 2026, -$4.1 million in Q4 2025, and $1.9 million in Q3 2025.